BiotechTube

dupilumab

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate-to-severe Atopic Dermatitis

Conditions

Moderate-to-severe Atopic Dermatitis

Trial Timeline

Jan 27, 2022 → Mar 10, 2023

NCT ID
NCT05203380

About dupilumab

dupilumab is a pre-clinical stage product being developed by Sanofi for Moderate-to-severe Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05203380. Target conditions include Moderate-to-severe Atopic Dermatitis.

What happened to similar drugs?

2 of 9 similar drugs in Moderate-to-severe Atopic Dermatitis were approved

Approved (2) Terminated (0) Active (7)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅dupilumabSanofiApproved
🔄SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
🔄Indacaterol + ControlNovartisPhase 3
🔄Dupilumab + PlaceboSanofiPhase 3
🔄PonesimodVanda PharmaceuticalsPhase 3
🔄sufentanil sublingual tablet 30 mcgTalpheraPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT05906706Pre-clinicalCompleted
NCT07316114Pre-clinicalRecruiting
NCT07467564Pre-clinicalRecruiting
NCT07187089ApprovedWithdrawn
NCT07112378Phase 3Recruiting
NCT07052396Pre-clinicalRecruiting
NCT07276425Pre-clinicalRecruiting
NCT06695897Pre-clinicalRecruiting
NCT06693531Pre-clinicalRecruiting
NCT06415175Pre-clinicalActive
NCT06556264ApprovedRecruiting
NCT06352073ApprovedRecruiting
NCT06293053Phase 3Recruiting
NCT05983068ApprovedActive
NCT06234761Pre-clinicalRecruiting
NCT05991323Pre-clinicalActive
NCT06192563Pre-clinicalRecruiting
NCT06169527Pre-clinicalActive
NCT06393946Pre-clinicalActive
NCT05831176Phase 2Active

Competing Products

13 competing products in Moderate-to-severe Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
SHR-1314Jiangsu Hengrui MedicinePhase 1
25
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
36
Indacaterol + ControlNovartisPhase 3
40
DeucravacitinibBristol Myers SquibbPre-clinical
33
Dupilumab + PlaceboSanofiPhase 3
40
dupilumabSanofiApproved
43
PonesimodVanda PharmaceuticalsPhase 3
37
sufentanil sublingual tablet 30 mcgTalpheraPhase 3
30
Zalviso™ 15 mcgTalpheraPhase 3
30
sufentanil sublingual 30 mcg tabletTalpheraPhase 3
30